Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036


News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294;

React to this article
Latest news on GILEAD SCIENCES, INC.
05/20 GILEAD SCIENCES : Diane McKeel did not disclose connection between her son, her ..
05/20 GILEAD SCIENCES : Patent Issued for Methods for Preparing Anti-Viral Nucleotide ..
05/20 GILEAD SCIENCES : Researchers Submit Patent Application, "Combination Therapy fo..
05/20 GILEAD SCIENCES : to Present at the Bank of America Merrill Lynch 2015 Health Ca..
05/20 GILEAD SCIENCES : Patent Challenges In Five Countries Dispute Validity Of Gilead..
05/18 GILEAD SCIENCES : to Present at the UBS 2015 Global Healthcare Conference on Tue..
05/13 ABZENA : Says Gilead Advancing Antibody To Further Clinical Trials
05/12DJMcKesson Revenue Up 19% on Distribution Unit Sales, Celesio Stake
05/12 GILEAD SCIENCES : to Present at the Bank of America Merrill Lynch 2015 Health Ca..
05/12 GILEAD SCIENCES : Sanders Urges VA to Use Emergency Powers to Save Lives of Vete..
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials